DOCSLIB.ORG

GALZIN CAPSULES Generic Name: Zinc Acetate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GALZIN CAPSULES Generic Name: Zinc Acetate CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: Application Number : 020458 Trade Name : GALZIN CAPSULES Generic Name: Zinc Acetate Capsules Sponsor : Lemon Company Approval Date: January 28, 1997 NDA 20-458 Lemmon Company JAN 28 IW? Attention: Deborah Jaskot 650 CathillRoad ScIIersville, PA 18960 Dear Ms. Jaskot: Please refer to your Jue 21, 1994 new dmg application submitied under section 505(b) of the Federal FOOL Drug, ad Cosmetic Act for Galzk (Zinc Acetate) Capsules, 25 and 50 mg. We acknowledge receipt of your amendments dated September 6 and October 31, 1995, January 3 and 29, March 27, April 8, August 7, September 13 and 24, october 8 and 14, 1996. - This new drug apphcation provides for Galzin at a dose of 25-50 mg three times daily as maintenance treatment for patients with Wilson’s disease initially treated with a chelating agent. We have completed the review of this application and have concluded that adequate information has been presented t.odemonstrate that the drug is safe and effective for use as recommended in the fwl printed labeling submitted cm October 8, 1996. Accordingly, the application is approved effective on the date of this letter. We remind you of your Phase 4 commitments specified in your submission dated August 29, 1995 and confirmed in our letter of January 27, 1997. These commitments, along with any completion dates agreed upon, are listed below. protocols, dab, and final repoflsshould be submitted to your IND for this product and a COPY of the cover l~er sent to this NDA. Should an IND not be required to meet your Phase 4 co[~tments, please submit pr~ioco], data, and final reports to this NDA as correspondences. h addit:~n, we requestunder 21 CFR 314.81(b)(2)(vii) that you include in your annual report to 1~5 app]ica~ion, a sta~s sumar~ of ~ac~ co~i~ent. The SUNUS su~~ should include the number of patients entered in each s~dy, expectedcompletion and submissionda~s, and any changes ~ plans since the ‘lastannual report. For administrative purposes, all — MA 20-458 Page 2 submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly desigm~d “Phse 4 Commitments.” A( we next printing of the package insert, please make the revisions specified below and notify the Agency in the next annual report: 1. Overall: a. The trademarksymbol, ( m ) should be added to each instance of the word Galzin. b. The top of the insert should be revised from “GALZIN ‘“ (Zinc Acetate)” to “GALZIN ‘“ (Zinc Ace[ate) Capsules. ” 2. CLINICAL TRIALS section: The statement at the end of the table should be revised from “Some patients had more than one balance studies... ” to “Some patients had more than one balance study... ” 3. DOSAGE AND ADMINISTRATION section: a. The first sentence should be revised from “The recommended adult dose is 50 mg of elemental zinc... ” to “The recommended adult dose is 50 mg as zinc... ” Further, the following revisions should be made to the DESCRIPTION section to ensure continuity of the package insert: b. The f~st sentence should be revised from “Zinc Acetate as the dihydrate is a salt of metallic zinc used to inhibit... ” to “Zinc Acetate as the dihydrate is a salt of zinc used to itilbit...” c. The first sentence of the third paragraph should be revised from “GALZIN (Zinc Acetate) Capsules contain the equivalent of 25 or 50 mg of elemental .. zinc... ” to “GALZJW (Zinc Acetate) Capsules contain the equivalent of 25 or 50 mg of zinc... ” In addition, please submit ~ee copiesof the introductory promotional material that you Propose to use for this product. AHproposed materials should be submitted in draft or mock- Up fen, not ~na] print please ~ubmit one COpyto thisDivision and two copies of boti the NDA 20458 page 3 promotional material and the package insert directly to: Food and Drug Administration Division of Drug Marketing, Advertising and Communications, HFTWIO 5600 Fishers Lane Roclcville, Maryland 208S7 Validation bf the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Ncvmtheless, we expect your continued coopmation to resolve my problems that maY be identified. We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81. If you have any questions, please contact Melodi McNeil, Consumer Safety Officer, at (301) 443-0483. cc: Original NDA 20-458 Sincerely yours, HFD-180/Div. files HFD-180/CSO/M .McNeil HFD-180/Duf& HFD-180/Chen Stephen B. Fredd, M.D. HFD-180/Choudwy Director HFD-720/Huque Division of Gastrointestinal and Coagulation HFD-820/C)~DC Division Director Drug Products DIs~CT OFFICE Office of Drug Evaluation III HF-2/Medwatch (with labeling) Center for Drug Evaluation and Research HFD-92/DDM-DIAB (with labeling) HFD.40/DDMAC (with labeling) . HFD-61310GD (with labeling) HFD-735/DPE (with labeling) - for all NDAs and supplements for adverse reaction changes, 14F]-20/press office (withlabeling) HFD.021/Acs (with labeling) drafied: mm/December 12, 1996ic:\wpFdes\cso\20458612.ap r/d Ini(ia]s: Wohnson 1/22/97 SFtedd 1/27/97 w yVj?if? final: January 28, 1997 APPROVAL(AP) [with Phase 4 Commitments] NDA20-458 GALZIN~ (ZINCACETATE) 25 mgand50 mg PACKAGEINSERTLABELING R 247 12445 1111I # GAIZIW (Zinc Acetate) 0ESCRIP710N Zmc AIMate as the Oihydrafe IS a $sii of meldhc 2itSCused to inhibd On Xnc@ion al copper in pafimfs sshhW!lson’s dwse Its chemmdl Iormula IS C,tiJf4Zn.2Hz0, M W 21951 Z!nc Acetate occurs as whd.$ crystals or granules, Ireeti soluble in waler and m bollmg alcohol an6 Wghtly soluble m alcohol GALZIN (Zinc Acetate) Capsules contain the eqwvaknt of 25 or 50 mg of elemental zinc, m addfllon to com starch and magrwslum Slearale m gelatln capsules The 25 mg capsule shells contain btamum dtonde a“d Ihe 50 mg cap. sule shelis contan Idanwm d!oxlde methyl paraben and Propyl paraben The 25 mg capsule shellscontain FD&C Blue #1, the 50 mg capsule shells contm FD6C Red #40 D&C Red t28, and O&C Yellow #10 CLINICAL PHARMACOLOtlY Introduction Wdsons Disease (hepatolenhcular degenerahon) 4San aulosomal recesswe metabolfc defecl m Mp.mc exc,etlon of copper !n the bile resulllng m accumulation of excess copper m The Ihver,and subsequently m othel organs mclud. mg the bmm k,dneys eym bone and muscles (n lh!s dnease heDalOcytes store excess cODDer bul when tklr capacwy IS exceedeo copp?r IS leleased mto the blood and IS taken up In efl”rahepatm sales, such as the brain result. mg !n molol disorders (atax!a tremors speech dithcultes) and psychlatrm man$fesfabons (mdabdoy depressmn, deterloral,on of work performance] Redmt!lbullon of excess copper m hepatocyfes leads to hepatocellular mjufy, mllammatlon necros[s and eventual clrrhosls Patients may present ckmcally with predomman fly hepahc neurc- logac or psychtalc!c sympwms The dnease has been trealed by restricting coppet m the d!el. and the use of chelatlng aWnts to bmd free copper to reduce Its foxtclfy and Iaclldate its excretion The purpose of mltlal treatment of symplomahc pabents wilh a chebl. mg a9er0 IS 10 deloxty copper Once the patlenls symptoms havs stabtlued climcally maintenance treatment begins Cltmcalmeasures are used to determme whether the patC?ntremams stable @.?ePRECAUTIONS Monitoring Pafienlsl The achve mooety m Z!nc Acetate IS mm cation Regardless of the hgand, zinc blrxk$ the mtestmal absorphon of cop pw Irom the diet and Ihe reabsorpmm 01 endogenously Secrelsd copwr such as ihat from the sahva, gastric juice and btk Zmc reduces the!pmductton of metallottwmem m ths eNerOCfl’? a protein that binds cDppeI thereby pre- venhnq !ts serosal transfer mlo the blood The bound copper IS then lost m the stool following desquamatlon of ths mlestmal cells Pharmacohinelic.s Because the proposed sde of ac(vm at zmc IS an effect on copper up!ake at ths level of the mh?slmal cell, pharma. Cokmet,c eva!ual)ons na$ed on blood levels 01zmc do no! prov,de useful mformahon on zinc b!oavaltabdm at the We Ot acllon Determmallons cdZinc content m the Ihve!anti the plasma Zmc Concemratmn afler the oral adiyn,strat,on Ot Zmc Acelale have qteldcd mcons,slenl results However foods and beverages have been shown to decrease the uQ!ake of ZIIICfhereby decreasw the levels of zmc III the Plasma of healthy volunteers For liws reason, the oral Oose of zmc should be separated from food and beverages, other than water by at Isast ons f!our Pharmacodynamies in pharmaccdynamlc studies, the methods used included net copper balance and radtolabekd copper uptake m Wdson’s disease uabents These Sludles showed that a reolmen of SD ma t., d of Zmc Acetate was eftecuve m lmduc. mg a negatwe mean copper balance (-O 44 mgiday) and ai adequate mean ‘Cu uptake (0 82% at the admmmtered aosel A regimen of 25 mu t l.d of Ztnc Acetate was also pf!drmacodynammally acove but fewer paberds have been treated wdh this regimen than 50 mg t I d CLINICAL 7RIALS In the single center Ltmted States tr!al 6U pahents wtth WIkOns titsease (31 mate. 29 female) who had ads@MSe detoxdlcatlon 01 copper after mdlal Chelatlon therapy WEre enlered mto a coppel balance study of varmus doss rer- nmens of Zinc Acetate Paoents were hospitallzsd 10 csrefully control iocd and Ihquldintake Food, urine and feces were analyzed ior copper c,mlent, and copper balance was dehned as the ddfererue between coppet lmfaksand cop w ehmmat!on{excretlon over a 10-day period A pabent was considered m adequate copper balance II the result wss less than +025 mg copperlday Resuhs for the groups m each dose regimen tested and for adequacy al mdwtdus[ resMts are prov!ded m the Iollowing table Number of Patients Dose Regimen Mean Coppsr Inadequately (mg zmc x numbw of Balance ControledIlOfal number da!ly dOSeSl N’ (m#day) of pahenls sfuded 50X3 70 -036 6/70 50X2 5 -016 0/5 25x4 5 -0 2f 0i3 25x3 fl -0.18 Illf 375x2 4 -0.02 f/4 75X1 8 016 2A 25x2 4 015 1/4 25x1 10 .0.37 2/1 o 25x6 12 005 4/12 50X1 f 01 0/1 50X5 11 -0.3 ill 1 o 6 052 — “N.
Load more

Recommended publications
  • Flexible Plasmonic Sensing Substrates and Their Application in Explosive Sensing Justin Bae Washington University in St Louis
    Washington University in St. Louis Washington University Open Scholarship Engineering and Applied Science Theses & McKelvey School of Engineering Dissertations Spring 5-17-2017 Flexible Plasmonic Sensing Substrates and their application in Explosive Sensing Justin Bae Washington University in St Louis Srikanth Singamaneni Washington University in Saint Louis Follow this and additional works at: https://openscholarship.wustl.edu/eng_etds Part of the Engineering Commons Recommended Citation Bae, Justin and Singamaneni, Srikanth, "Flexible Plasmonic Sensing Substrates and their application in Explosive Sensing" (2017). Engineering and Applied Science Theses & Dissertations. 231. https://openscholarship.wustl.edu/eng_etds/231 This Thesis is brought to you for free and open access by the McKelvey School of Engineering at Washington University Open Scholarship. It has been accepted for inclusion in Engineering and Applied Science Theses & Dissertations by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS School of Engineering and Applied Science Department of Mechanical Engineering and Materials Science Thesis Examination Committee: Srikanth Singamaneni, Chair Guy Genin Jeremiah Morrissey Flexible Plasmonic Sensing Substrates and their application in Explosive Sensing by Sang hyun Justin Bae A thesis presented to the School of Engineering of Washington University in St. Louis in partial fulfillment of the requirements for the
    [Show full text]
  • Comparison of Zinc Acetate and Propionate Addition on Gastrointestinal Tract Fermentation and Susceptibility of Laying Hens to S
    ENVIRONMENT, HEALTH, AND BEHAVIOR Comparison of Zinc Acetate and Propionate Addition on Gastrointestinal Tract Fermentation and Susceptibility of Laying Hens to Salmonella enteritidis During Forced Molt R. W. Moore,*,†,1 S. Y. Park,†,2 L. F. Kubena,* J. A. Byrd,* J. L. McReynolds,* M. R. Burnham,*,3 M. E. Hume,* S. G. Birkhold,† D. J. Nisbet,* and S. C. Ricke†,4 *USDA-ARS, Southern Plains Agricultural Research Center, Food and Feed Safety Research Unit, College Station, Texas 77845; and †Department of Poultry Science, Texas A&M University, College Station, Texas 77843 ABSTRACT Feed deprivation is the most common Body weight losses were significantly higher in the M, method used to induce molting and stimulate multiple ZPR, and ZAC treatments than in the NM treatment. egg-laying cycles in laying hens for commercial egg pro- Crop lactic acid decreased more in M, ZPR, and ZAC duction. Unfortunately, an increased risk of Salmonella treatments than in NM hens in trial 2. Crop pH was < enteritidis (SE) colonization may result from the use of significantly (P 0.05) lower in NM hens than in M, ZAC, this method. Methods to stimulate multiple egg-laying and ZPR hens in trial 2. Although cecal individual or total volatile fatty acids (VFA), and lactic acid were not cycles without increasing the risk of SE are needed. In > each of 3 experiments, hens over 50 wk of age were di- significantly (P 0.05) different between NM hens and M, ZAC and ZPR hens in trial 1, lactic acid was signifi- vided into groups of 12 and placed in individual laying cantly (P < 0.05) higher in NM hens than in M, ZAC and cages.
    [Show full text]
  • Zinc Acetate MSDS # 793.00
    Material Safety Data Sheet Page 1 of 2 Zinc Acetate MSDS # 793.00 Section 1: Product and Company Identification Zinc Acetate Synonyms/General Names: Acetate Salt of Zinc; zinc acetate dihydrate Product Use: For educational use only Manufacturer: Columbus Chemical Industries, Inc., Columbus, WI 53925. 24 Hour Emergency Information Telephone Numbers CHEMTREC (USA): 800-424-9300 CANUTEC (Canada): 613-424-6666 ScholAR Chemistry; 5100 W. Henrietta Rd, Rochester, NY 14586; (866) 260-0501; www.Scholarchemistry.com Section 2: Hazards Identification White crystalline granules; slight acetic acid odor. HMIS (0 to 4) Health 2 WARNING! Severe body tissue irritant and moderately toxic by ingestion. Fire Hazard 0 Target organs: None known. Reactivity 0 This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200). Section 3: Composition / Information on Ingredients Zinc Acetate (5970-45-6), 100% Section 4: First Aid Measures Always seek professional medical attention after first aid measures are provided. Eyes: Immediately flush eyes with excess water for 15 minutes, lifting lower and upper eyelids occasionally. Skin: Immediately flush skin with excess water for 15 minutes while removing contaminated clothing. Ingestion: Call Poison Control immediately. Rinse mouth with cold water. Give victim 1-2 cups of water or milk to drink. Induce vomiting immediately. Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Section 5: Fire Fighting Measures When heated to decomposition, emits acrid fumes. 0 Protective equipment and precautions for firefighters: Use foam or dry chemical to extinguish fire. 1 0 Firefighters should wear full fire fighting turn-out gear and respiratory protection (SCBA).
    [Show full text]
  • Protective Effects of Zinc-L-Carnosine /Vitamin E on Aspirin- Induced Gastroduodenal Injury in Dogs
    PROTECTIVE EFFECTS OF ZINC-L-CARNOSINE /VITAMIN E ON ASPIRIN- INDUCED GASTRODUODENAL INJURY IN DOGS MASTER’S THESIS Presented in Partial Fulfillment of the Requirements for the Master of Science Degree in the Graduate School of the Ohio State University By Mieke Baan, DVM, MVR ***** The Ohio State University 2009 Master’s Examination Committee: Professor Robert G. Sherding, Adviser Professor Stephen P. DiBartola Associate Professore Susan E. Johnson Approved by Adviser Veterinary Clinical Sciences Graduate Program ! Copyright by Mieke Baan 2009 ABSTRACT Zinc plays a role in many biochemical functions, including DNA, RNA, and protein synthesis. The dipeptide carnosine forms a stable complex with zinc, which has a protective effect against gastric epithelial injury in-vitro and in-vivo. This randomized double-blinded placebo-controlled study investigated the protective effects of zinc-L-carnosine in combination with alpha-tocopheryl acetate (vitamin E) on the development of aspirin-induced gastrointestinal (GI) lesions in dogs. Eighteen mixed-breed dogs (mean 20.6 kg) were negative for parasites, and had normal blood work evaluations, and gastroduodenoscopic exams. On days 0 – 35, dogs were treated with 1 tablet (n=6) or 2 tablets (n=6) of 30 mg zinc-L-carnosine/ 30 IU vitamin E q12h PO, or a placebo (n=6). On days 7 – 35, all dogs were given 25 mg/kg buffered aspirin q8h PO. Endoscopy was performed on Days -1, 14, 21, and 35, and GI lesions (hemorrhages, erosions, or ulcers) were scored using a 12-point grading scale. Repeated measures ANOVA was used for statistical evaluation. The significance level was set at p ! 0.05.
    [Show full text]
  • Preferred Drug List 4-Tier
    Preferred Drug List 4-Tier 21NVHPN13628 Four-Tier Base Drug Benefit Guide Introduction As a member of a health plan that includes outpatient prescription drug coverage, you have access to a wide range of effective and affordable medications. The health plan utilizes a Preferred Drug List (PDL) (also known as a drug formulary) as a tool to guide providers to prescribe clinically sound yet cost-effective drugs. This list was established to give you access to the prescription drugs you need at a reasonable cost. Your out- of-pocket prescription cost is lower when you use preferred medications. Please refer to your Prescription Drug Benefit Rider or Evidence of Coverage for specific pharmacy benefit information. The PDL is a list of FDA-approved generic and brand name medications recommended for use by your health plan. The list is developed and maintained by a Pharmacy and Therapeutics (P&T) Committee comprised of actively practicing primary care and specialty physicians, pharmacists and other healthcare professionals. Patient needs, scientific data, drug effectiveness, availability of drug alternatives currently on the PDL and cost are all considerations in selecting "preferred" medications. Due to the number of drugs on the market and the continuous introduction of new drugs, the PDL is a dynamic and routinely updated document screened regularly to ensure that it remains a clinically sound tool for our providers. Reading the Drug Benefit Guide Benefits for Covered Drugs obtained at a Designated Plan Pharmacy are payable according to the applicable benefit tiers described below, subject to your obtaining any required Prior Authorization or meeting any applicable Step Therapy requirement.
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Attachment 3-1 Guidance for Developing Ecological Soil
    Attachment 3-1 Guidance for Developing Ecological Soil Screening Levels (Eco-SSLs) Eco-SSL Standard Operating Procedure (SOP # 1): Plant and Soil Invertebrate Literature Search and Acquisition OSWER Directive 92857-55 November 2003 This page intentionally left blank OVERVIEW Currently, there is a lack of clear guidance in setting terrestrial effect thresholds when conducting risk assessments. Without an EPA-approved, peer-reviewed, ecologically-based terrestrial effect database, the process to develop thresholds is problematic both to EPA, other federal agencies, states, and concerned private parties. Identification of published toxicity studies on invertebrates, microbial processes and plants is a key step in the derivation of benchmarks. The purpose of the Task Group 4, Standard Operating Procedure Number 1: Literature Search and Acquisition (referred to as TG4-SOP#1) is to document procedures used to identify and acquire potentially relevant toxicology literature for use in setting ecological soil screening levels. The literature search strategy is designed to locate worldwide terrestrial toxicity literature that includes the effects of chemicals of concern on terrestrial soil-dwelling invertebrates and plants. The literature acquisition process is designed to ensure timely acquisition of relevant publications. LITERATURE IDENTIFICATION Potentially relevant literature for developing ecological soil screening levels (Eco-SSLs) is identified by examining hard copies of relevant journals, bibliographies and guidance publications and through the use of a comprehensive computerized literature search strategy. These procedures are designed to locate worldwide terrestrial toxicology literature that includes the effects of specific toxic substances with an emphasis on exposure via soil. Paper-based Literature Identification The paper-based literature identification process includes the scanning of relevant review article bibliographies and key journals held in the U.S.
    [Show full text]
  • Zinc Acetate
    Zinc acetate sc-253848 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Zinc acetate STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY: ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C4-H6-O4-Zn, C4-H6-O4-Zn-2(H2O), Zn(C2-H3-O2)2, Zn(C2-H3-O2)2.2(H2O), "acetic acid zinc salt dihydrate", "dicarbomethoxyzinc dihydrate", "zinc acetate anhydrous", "acetic acid zinc (II) salt dihydrate", "J.T. Baker 4296 4297 4304 5658", "Mallinckrodt 8740" Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 2 Extreme=4 CANADIAN WHMIS SYMBOLS 1 of 12 EMERGENCY OVERVIEW RISK Harmful if swallowed. Irritating to eyes, respiratory system and skin. Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Soluble zinc salts produces irritation and corrosion of the alimentary tract with pain, and vomiting. Death can occur due to insufficiency of food intake due to severe narrowing of the esophagus and pylorus.
    [Show full text]
  • United States Patent (19) (11) 4,354,029 Kaiser Et Al
    United States Patent (19) (11) 4,354,029 Kaiser et al. 45) Oct. 12, 1982 54) PREPARATION OF (56) References Cited 2-SUBSTITUTED-2-OXAZOLINES WITH ORGANIC ZINC SALT CATALYSTs U.S. PATENT DOCUMENTS 3,813,378, 5/1974 Whitte et al........................ 548/239 (75) Inventors: Mark E. Kaiser, Midland, Mich.; 3,917,631 11/1975 Arlt..................................... 548/239 David L. Larson, Cookeville, Tenn. 4,014,880, 3/1977, Dowd et al. ........................ 548/239 (73) Assignee: The Dow Chemical Company, 4,035,309 7/1977 Brois ................................... 548/239 Midland, Mich. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 325,948 1483682 8/1977 United Kingdom . 22) Filed: Nov.30, 1981 Primary Examiner-Anton H. Sutto Related U.S. Application Data Attorney, Agent, or Firm-Charles J. Enright (6) Continuation of Ser. No. 966,696, Dec. 5, 1978, aban 57 ABSTRACT doned, which is a continuation-in-part of Ser. No. 2-Substituted-2-oxazolines are prepared by contacting 758,279, Jan. 10, 1977, abandoned, and Ser. No. N-(2-hydroxyalkyl)carboxamides with a small but cata 875,280, Feb. 6, 1978, abandoned. lytic amount of an organic zinc salt at an elevated tem (51) Int. Cl... CO7D 263/12 perature. (52) U.S.C. ........... (58). Field of Search......................................... 548/239. 8 Claims, No Drawings 4,354,029 1 2 . PREPARATION OF. SUMMARY OF THE INVENTION 2-SUBSTITUTED-2-OXAZOLNES WITH A new process for making 2-substituted-2-oxazolines ORGANICZNC SALT CATALYSTS has now been discovered. The new process comprises reacting by contacting in a liquid phase an N-(2-hydrox CROSS-REFERENCE TO RELATED yalkyl)carboxamide with a small but catalytic amount APPLICATIONS of an organic zinc salt.
    [Show full text]
  • Wilzin, INN-Zinc Acetate Dihydrate
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Wilzin. For information on changes after approval please refer to module 8. 1. Introduction Wilzin contains zinc acetate dihydrate as active substance. With the present application, the applicant sought a marketing authorisation in the following indication: “Maintenance treatment of patients with Wilson’s disease. Wilzin can be administered in symptomatic patients after initial decoppering therapy with a chelating agent or from the beginning in presymptomatic patients.” Wilson's Disease Wilson's disease (also known as hepatolenticular degeneration) is an inherited autosomal recessive disorder characterised by the accumulation and toxicity of copper in various tissues. Copper is an essential trace element and an important metal co-factor for many enzymes. Normally, excess dietary copper is bound in the hepatocyte by cytoplasmic proteins, particularly metallothioneins (cysteine-rich intracellular proteins capable of binding and sequestering ions), then incorporated into plasma ceruloplasmin or excreted in the bile (Brewer et al., 1992). In Wilson’s disease, the gene encoding for a membrane-bound copper-transporting P-type ATPase (ATP7B) is defective, leading to insufficient biliary excretion of copper as well as to reduced incorporation of copper into ceruloplasmin. As a result of the positive copper balance, copper accumulates first in the liver, and later in the brain (Cuthbert 1995). The physiopathology of Wilson’s disease is linked to copper toxicity, as affected organs contain higher than normal levels of copper, which is implicated in deleterious oxidation of lipids and proteins and in free radical formation (Cuthbert 1995; Menkes 1999). The natural history begins with a pre-symptomatic period of positive copper balance and copper accumulation in the liver where subclinical cirrhosis develops.
    [Show full text]
  • Chemical Names and CAS Numbers Final
    Chemical Abstract Chemical Formula Chemical Name Service (CAS) Number C3H8O 1‐propanol C4H7BrO2 2‐bromobutyric acid 80‐58‐0 GeH3COOH 2‐germaacetic acid C4H10 2‐methylpropane 75‐28‐5 C3H8O 2‐propanol 67‐63‐0 C6H10O3 4‐acetylbutyric acid 448671 C4H7BrO2 4‐bromobutyric acid 2623‐87‐2 CH3CHO acetaldehyde CH3CONH2 acetamide C8H9NO2 acetaminophen 103‐90‐2 − C2H3O2 acetate ion − CH3COO acetate ion C2H4O2 acetic acid 64‐19‐7 CH3COOH acetic acid (CH3)2CO acetone CH3COCl acetyl chloride C2H2 acetylene 74‐86‐2 HCCH acetylene C9H8O4 acetylsalicylic acid 50‐78‐2 H2C(CH)CN acrylonitrile C3H7NO2 Ala C3H7NO2 alanine 56‐41‐7 NaAlSi3O3 albite AlSb aluminium antimonide 25152‐52‐7 AlAs aluminium arsenide 22831‐42‐1 AlBO2 aluminium borate 61279‐70‐7 AlBO aluminium boron oxide 12041‐48‐4 AlBr3 aluminium bromide 7727‐15‐3 AlBr3•6H2O aluminium bromide hexahydrate 2149397 AlCl4Cs aluminium caesium tetrachloride 17992‐03‐9 AlCl3 aluminium chloride (anhydrous) 7446‐70‐0 AlCl3•6H2O aluminium chloride hexahydrate 7784‐13‐6 AlClO aluminium chloride oxide 13596‐11‐7 AlB2 aluminium diboride 12041‐50‐8 AlF2 aluminium difluoride 13569‐23‐8 AlF2O aluminium difluoride oxide 38344‐66‐0 AlB12 aluminium dodecaboride 12041‐54‐2 Al2F6 aluminium fluoride 17949‐86‐9 AlF3 aluminium fluoride 7784‐18‐1 Al(CHO2)3 aluminium formate 7360‐53‐4 1 of 75 Chemical Abstract Chemical Formula Chemical Name Service (CAS) Number Al(OH)3 aluminium hydroxide 21645‐51‐2 Al2I6 aluminium iodide 18898‐35‐6 AlI3 aluminium iodide 7784‐23‐8 AlBr aluminium monobromide 22359‐97‐3 AlCl aluminium monochloride
    [Show full text]
  • The Cations Suite
    The Cations Suite For screening of protein crystallization conditions The Cations Suite provides: A ready-to-use kit format to which only protein needs to be added, for easy and fast screening 96 precisely defined chemical solutions containing various salts at two concentrations and four different pH values Salts as precipitant for protein crystallization The different solutions in a mini-grid format to easily view trends for each different salt and pH concentration The Cations Suite is available in a wide range of formats to suit all scales and throughputs. EasyXtal Refill-Hit Solutions can be used to develop grids around the original hit conditions. An overview of the composition of the 96 solutions together with an order number for the corresponding Refill-Hit Solution can be found on pages 2 and 3. The location of each Refill-Hit Solution number is given in the diagram below. Location of Refill-Hit Solutions in 24-Well and 96-Well Plate Formats 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 12 A 1 2 3 4 5 6 A 49 50 51 52 53 54 A 1 2 3 4 5 6 7 8 9 10 11 12 B 7 8 9 10 11 12 B 55 56 57 58 59 60 B 13 14 15 16 17 18 19 20 21 22 23 24 C 13 14 15 16 17 18 C 61 62 63 64 65 66 C 25 26 27 28 29 30 31 32 33 34 35 36 D 19 20 21 22 23 24 D 67 68 69 70 71 72 D 37 38 39 40 41 42 43 44 45 46 47 48 24-well plate 1 of 4 24-well plate 3 of 4 E 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 1 2 3 4 5 6 F 61 62 63 64 65 66 67 68 69 70 71 72 G 73 74 75 76 77 78 79 80 81 82 83 84 A 25 26 27 28 29 30 A 73 74 75 76 77 78 B 31 32 33 34 35 36 B 79 80 81 82 83 84 H 85 86 87 88 89 90 91 92 93 94 95 96 C 37 38 39 40 41 42 C 85 86 87 88 89 90 96-well plate D 43 44 45 46 47 48 D 91 92 93 94 95 96 24-well plate 2 of 4 24-well plate 4 of 4 Sample & Assay Technologies The Cations Suite Composition Table Cat.
    [Show full text]